These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31697804)

  • 1. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
    Patel AB; Franzini A; Leroy E; Kim SJ; Pomicter AD; Genet L; Xiao M; Yan D; Ahmann JM; Agarwal AM; Clair P; Addada J; Lambert J; Salmon M; Gleich GJ; Cross NCP; Constantinescu SN; O'Hare T; Prchal JT; Deininger MW
    Blood; 2019 Dec; 134(26):2388-2398. PubMed ID: 31697804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.
    Tsuruta-Kishino T; Koya J; Kataoka K; Narukawa K; Sumitomo Y; Kobayashi H; Sato T; Kurokawa M
    Oncogene; 2017 Jun; 36(23):3300-3311. PubMed ID: 28068330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
    Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
    Maddali M; Kulkarni UP; Ravindra N; Jajodia E; Arunachalam AK; Suresh H; Venkatraman A; George B; Mathews V; Balasubramanian P
    Ann Hematol; 2020 May; 99(5):983-989. PubMed ID: 32277273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications.
    Pourcelot E; Trocme C; Mondet J; Bailly S; Toussaint B; Mossuz P
    Exp Hematol; 2014 May; 42(5):360-8. PubMed ID: 24463275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
    Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
    N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
    PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
    Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
    Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
    Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
    Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
    Pasca S; Chifotides HT; Verstovsek S; Bose P
    Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with
    Socoro-Yuste N; Čokić VP; Mondet J; Plo I; Mossuz P
    Mol Cancer Res; 2017 Jul; 15(7):852-861. PubMed ID: 28314843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.